Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% and 70% editing in hepatocytes1, respectively New AATD data reinforced the safety and precision of Tessera's proprietary LNP delivery system, demonstrating that it was well tolerated in NHP with high liver specificity and no off-target activity detected Preclinical data fo…

Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene WritingPrograms and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

May 17, 2025 06:00 ET  | Source: Tessera Therapeutics Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% and 70% editing in hepatocytes1, respectively New AATD data reinforced the safety and precision of Tessera’s proprietary LNP delivery system, demonstrating that […]